DaVita (NYSE:DVA) Sets New 52-Week High – Should You Buy?

DaVita Inc. (NYSE:DVA)’s stock price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $218.50 and last traded at $216.6460, with a volume of 509 shares trading hands. The stock had previously closed at $217.04.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. TD Cowen boosted their price target on shares of DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a report on Monday, May 11th. Zacks Research raised shares of DaVita from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. UBS Group lifted their target price on shares of DaVita from $190.00 to $235.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Deutsche Bank Aktiengesellschaft upgraded shares of DaVita from a “hold” rating to a “buy” rating and upped their price target for the stock from $126.00 to $220.00 in a research report on Wednesday, May 6th. Finally, Barclays raised their price target on shares of DaVita from $158.00 to $194.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, DaVita has a consensus rating of “Hold” and an average price target of $199.17.

DaVita Stock Performance

The company has a 50 day moving average of $188.58 and a 200 day moving average of $152.74. The stock has a market capitalization of $14.05 billion, a price-to-earnings ratio of 20.30, a P/E/G ratio of 0.71 and a beta of 0.91.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.33 by $0.54. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The company had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.36 billion. During the same quarter in the previous year, the company posted $2.00 EPS. The firm’s quarterly revenue was up 6.0% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, equities analysts predict that DaVita Inc. will post 15.07 EPS for the current fiscal year.

Insider Transactions at DaVita

In related news, CFO Joel Ackerman sold 51,471 shares of the company’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the completion of the sale, the chief financial officer owned 132,434 shares of the company’s stock, valued at approximately $25,440,571.40. This represents a 27.99% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kathleen Alyce Waters sold 15,405 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the sale, the insider owned 109,194 shares of the company’s stock, valued at approximately $22,756,029.60. The trade was a 12.36% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On DaVita

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Root Financial Partners LLC lifted its position in DaVita by 128.0% during the first quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock worth $29,000 after buying an additional 105 shares in the last quarter. Elevation Wealth Partners LLC grew its holdings in shares of DaVita by 147.3% in the fourth quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock valued at $31,000 after purchasing an additional 165 shares during the period. Caitlin John LLC acquired a new stake in DaVita during the fourth quarter worth about $34,000. Sankala Group LLC purchased a new position in DaVita during the fourth quarter worth about $39,000. Finally, Canada Pension Plan Investment Board purchased a new position in DaVita during the second quarter worth about $43,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.